Por: RTTNews Health December 05, 2023
Eli Lilly and Company () announced that Zepbound injection is now available. It is indicated for adults with obesity, or those who are overweight and also have weight-related medical problems. The company said, following the , people living with obesity can now access Zepbound in six doses through a prescription. Effective Dec. 1, 2023, Zepbound was added to the National Preferred Formulary for Express Scripts and Cigna Healthcare. Effective... + full article
WPLG Local 10 USA Health November 09, 2023
A new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug, U.S. regulators announced Wednesday.The U.S. Food and Drug Administration approved Eli Lilly's drug, named Zepbound. The drug, also known as tirzepatide, helped dieters lose as much... + más
Popular diabetes drug Mounjaro could be FDA-approved for weight loss this year, company says | ABC News
Lawsuit filed against makers of Ozempic, Mounjaro over claims of 'gastrointestinal side effects' | ABC News
The New York Times USA Health November 09, 2023
The Food and Drug Administration on Wednesday approved an obesity drug from the company Eli Lilly that will be a direct competitor to the wildly popular Wegovy.The drug is called tirzepatide and will be sold under the name Zepbound. It joins a class of new medications that are... + más
‘There's no way that patients are going to be able to afford that.’ Why aren’t new drugs that can help you lose weight more widely used? | MarketWatch
Los Angeles Times USA Science November 09, 2023
A new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug, U.S. regulators announced Wednesday. The U.S. Food and Drug Administration approved Eli Lilly's Zepbound, or tirzepatide. The drug helped dieters lose about a quarter of their body... + más
MarketWatch USA Business November 08, 2023
Lilly (LLY) took a direct shot at Novo on Wednesday, saying it will set a list price for Zepbound of $1,059.87 for a month’s supply, which it noted is lower than Wegovy’s list price of $1,349.02. That lower price point for Zepbound hints at a coming commercial rivalry with... + más
FDA approves a new weight loss drug, Zepbound from Eli Lilly | CBS News
As Eli Lilly Gears Up For Growth, Its CFO Prescribes Leading Indicators | Forbes
ABC7 USA Health November 08, 2023
A new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug, U.S. regulators announced Wednesday.The U.S. Food and Drug Administration approved Eli Lilly's Zepbound, or tirzepatide. The drug helped dieters lose about a quarter of their body... + más
CBS News USA Health November 08, 2023
The Food and Drug Administration approved a request by Eli Lilly on Wednesday to begin marketing its tirzepatide medication, which is branded as Mounjaro for diabetes, under a new brand for weight loss as well.While Mounjaro had already been used by some patients off-label for... + más
Eli Lilly Stock Jumps on Obesity Drug’s FDA Approval | MarketWatch
FDA approves new version of diabetes drug Mounjaro for weight loss | Los Angeles Times
10 WBNS USA Nation November 08, 2023
WASHINGTON — A new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug, U.S. regulators announced Wednesday. The U.S. Food and Drug Administration approved Eli Lilly's Zepbound, or tirzepatide. The drug about a quarter of their body... + más
About iurex | Privacy Policy | Disclaimer |